Company profile: Orchestra BioMed
1.1 - Company Overview
Company description
- Provider of biomedical solutions for procedure-based medicine: BackBeat CNT (investigational bioelectronic treatment for hypertension to reduce blood pressure and modulate autonomic nervous system responses); Virtue SAB (investigational drug/device delivering sirolimus during angioplasty without coating or permanent implants); and FreeHold Retractors for hands-free surgical retraction to improve visualization and procedural efficiency.
Products and services
- BackBeat Cardiac Neuromodulation Therapy (BackBeat CNT): An investigational bioelectronic system that targets hypertension by reducing blood pressure and modulating autonomic nervous system responses via cardiac neuromodulation
- FreeHold Retractors: Minimally invasive surgical devices that deliver hands-free, adjustable retraction to optimize visualization and improve procedural efficiency during procedure-based medicine
- Virtue Sirolimus AngioInfusion Balloon (Virtue SAB): A drug/device combination for artery disease treatment that delivers sirolimus during angioplasty without coating or permanent implants
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Orchestra BioMed
Recovery Force
HQ: United States
Website
- Description: Provider of MORPH, an on-body pre recovery and performance enhancement system, developed and manufactured by Recovery Force.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Recovery Force company profile →
Millipede Medical
HQ: United States
Website
- Description: Provider of a percutaneous, catheter-based solution for mitral valve repair and treatment of mitral and tricuspid regurgitation, restoring health and expanding options for physicians and patients globally.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Millipede Medical company profile →
Quantum Genomics
HQ: France
Website
- Description: Provider of effective, well-tolerated therapeutic treatments for cardiovascular diseases, focused on controlling high blood pressure and preventing related risks such as heart failure, addressing unmet medical needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quantum Genomics company profile →
Avantec Vascular
HQ: United States
Website
- Description: Provider of coronary and peripheral vascular medical devices, including the Duraflex Coronary Stent System for vascular disease treatment, Apollo Coronary Dilatation Catheter, Captus Vascular Retrieval System for retrieving foreign objects (guide wires, coils, balloons, catheters, filters), neurovascular and peripheral coils, peripheral atherectomy, and specialty coronary/peripheral drug-eluting stents.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Avantec Vascular company profile →
Retension Pharmaceuticals
HQ: United States
Website
- Description: Provider of healthcare solutions focused on RTN-001, a tissue-targeted PDE5 inhibitor designed to treat hypertension by enhancing nitric oxide action in the central pulmonary vasculature, promoting vasodilation and blood pressure control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Retension Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Orchestra BioMed
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Orchestra BioMed
2.2 - Growth funds investing in similar companies to Orchestra BioMed
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Orchestra BioMed
4.2 - Public trading comparable groups for Orchestra BioMed
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →